Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Western Digital Fiscal Q1 2026 Earnings Call - Accelerated AI-Driven Demand Fuels Massive Growth and Capacity Commitments
Western Digital reported a stellar fiscal Q1 2026, with revenue of $2.8 billion, a 27% year-over-year surge driven by robust demand for high-capacity nearline HDDs critical to AI and data center workl...
- Western Digital delivered $2.8 billion revenue in Q1 fiscal 2026, up 27% year-over-year, beating guidance on strong cloud and AI-driven demand.
- Gross margin improved 660 basis points YoY to 43.9%, helped by mix shift towards higher-capacity Ultra SMR drives and tight cost controls.
- Free cash flow reached $599 million despite a large tax payment, sustaining a free cash flow margin above 20%.
- +15 more takeaways
El Pollo Loco Q3 2025 Earnings Call - Positive Traffic Growth and Margin Expansion Validate Strategic Momentum
El Pollo Loco's Q3 2025 results reveal a brand gaining ground amid challenging market conditions, with positive system-wide traffic growth and meaningful margin expansion both at the restaurant and co...
- Q3 2025 system-wide traffic grew 1.6%, driven by franchise traffic growth of 2.5%, reflecting successful menu innovation and marketing efforts.
- New menu items like $9.99 quesadilla combos and burrito bowls have appealed to value-conscious consumers while preserving margins, with quesadillas now a permanent menu fixture.
- Operational excellence initiatives led to increased labor productivity and cost efficiency, helping restaurant-level operating margins grow 160 basis points to 18.3% in Q3.
- +10 more takeaways
Travere Therapeutics Q3 2025 Earnings Call - FILSPARI Sales Surge and FSGS FDA Approval Near
Travere Therapeutics delivered a strong Q3 2025 with continued robust growth of FILSPARI in IgA nephropathy, highlighted by $91 million in net sales and expanding physician adoption. The recent FDA mo...
- FILSPARI net sales in IgA nephropathy reached approximately $91 million in Q3, up over 155% year-over-year.
- FDA modified FILSPARI REMS program by removing embryo-fetal toxicity restriction and reducing liver monitoring to quarterly, aligning with routine practice and easing patient care.
- FILSPARI was included as a first-line treatment option in updated KDIGO guidelines for IgA nephropathy, marking a paradigm shift endorsed by nephrology KOLs.
- +7 more takeaways
iRhythm Technologies Inc. Q3 2025 Earnings Call - Record Growth, Strategic Expansion, and Positive Free Cash Flow Milestone
iRhythm Technologies posted a robust Q3 2025 with $192.9 million revenue, up 31% year-over-year, driven by record performance in both Zio Monitor and Zio AT product lines. The company is aggressively ...
- Q3 2025 revenue reached $192.9 million, marking 31% year-over-year growth driven by strong sales of Zio Monitor and Zio AT.
- Primary care expansion and 30 active Epic Aura EHR integrations (with 65 more underway) enhanced clinician workflow and contributed to a 25% volume increase within six months post-integration.
- The company generated nearly 12 million reports worldwide, evidencing broad adoption across hospital and ambulatory settings with larger integrated delivery networks converting system-wide to iRhythm.
- +12 more takeaways
Weave Communications Q3 2025 Earnings Call - AI and Integration Drive Accelerated Growth and Profitability
Weave Communications reported a strong Q3 2025 with accelerating revenue growth of 17.1% year-over-year, reaching $61.3 million and marking the 15th consecutive quarter above guidance. The company's v...
- Weave delivered $61.3 million in revenue, accelerating growth to 17.1% year-over-year and surpassing guidance for the 15th straight quarter.
- Gross margin reached a record 73%, up over 15 points since IPO, driven by leveraging cloud cost efficiencies.
- Free cash flow was $5 million for the quarter, reflecting improved operational discipline and scalability.
- +13 more takeaways
ICF International Q3 2025 Earnings Call - Resilient Commercial Growth Offsets Federal Challenges Amid Government Shutdown
ICF International's third quarter 2025 results reveal a company navigating turbulent federal government headwinds with strategic agility. While federal contract revenues tumbled nearly 30% year-over-y...
- ICF's Q3 2025 revenues totaled $465.4 million, down from $517 million year-over-year, reflecting federal government revenue declines.
- Federal government revenues fell 29.8% year-over-year, hindered by contract cancellations and a slowdown ahead of the government shutdown.
- Non-federal revenues (commercial, state/local, international) increased 13.8%, making up 57% of total revenues, up from 46% a year earlier.
- +7 more takeaways
OneSpan Q3 2025 Earnings Call - Software Subscription Growth Amid Hardware Decline and Strategic Transformation
OneSpan reported modest total revenue growth of 1% to $57 million in Q3 2025, powered by a strong 12% rise in subscription revenue despite continued pressure from declining hardware sales, which now m...
- OneSpan’s total revenue grew 1% year-over-year to $57.1 million in Q3 2025, driven mainly by a 12% increase in subscription revenue.
- Annual recurring revenue (ARR) increased 10% to $180 million, reflecting strong recurring software sales momentum.
- Subscription revenue growth was led by security (13%) and digital agreements (11%), with digital agreements hitting record operating income of 25% margin.
- +12 more takeaways
Textron Q3 2025 Earnings Call - Strong Aerospace Growth, MV-75 Program Advances, Leadership Transition
Textron reported a solid Q3 2025 with revenues rising 5% to $3.6 billion and segment profit jumping 26% to $357 million, driven by robust performance in aerospace and defense. Aviation delivered more ...
- Textron’s Q3 2025 revenues increased 5% to $3.6 billion, driven by aerospace and defense businesses.
- Segment profit surged 26% to $357 million, reflecting higher volumes and improved mix, notably in Aviation.
- Textron Aviation delivered 42 jets and 39 commercial turboprops, beating last year’s turboprops by 14 units.
- +12 more takeaways
Ardelyx Q3 2025 Earnings Call - IBSRELA Surges with Raised Guidance as Pipeline Revival Begins
Ardelyx reported a robust Q3 2025 with product revenues hitting $105.5 million, up 15% year-over-year, led by the powerhouse IBSRELA, which surged 92% to $78.2 million and drove the company to raise i...
- Q3 2025 product revenue reached $105.5 million, a 15% year-over-year increase driven by strong demand across the portfolio.
- IBSRELA revenue surged 92% year-over-year to a record $78.2 million, leading to raised 2025 revenue guidance to $270-$275 million.
- XPHOZAH revenue grew 9% sequentially to $27.4 million amid challenging dialysis market conditions and payer dynamics.
- +14 more takeaways
INmune Bio 3Q 2025 Earnings Call - Advancing Cordstrom Towards Regulatory Approval with Platform Expansion and Alzheimer’s Insights
INmune Bio’s third quarter 2025 earnings call underscores a transition into a pivotal phase focused on their advanced platform therapeutics. Cordstrom, targeting recessive dystrophic epidermolysis bul...
- INmune Bio is shifting focus post-Alzheimer’s Phase 2 trial to advance its three main platforms: Cordstrom, EXPRO, and Incuboom.
- Cordstrom targets RDEB, a systemic genetic disease causing skin fragility and multi-system complications, offering a potential first systemic therapy for this condition.
- Mission EB trial data showed Cordstrom significantly reduced itch, disrupting the itch-scratch-wound cycle that impairs healing and quality of life in pediatric patients.
- +12 more takeaways